Business Context and Reporting Period
This Form 8-K Current Report was filed by Mustang Bio, Inc. on January 19, 2024. The filing reports a corporate governance event regarding the appointment of an interim executive officer.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes.
Material Changes
- Appointment of Interim CFO: On January 19, 2024, the Company appointed James Murphy as Interim Chief Financial Officer.
- Roles: Mr. Murphy serves as the Company's Principal Financial Officer and Principal Accounting Officer.
- Compensation Structure: Mr. Murphy provides services pursuant to a consulting agreement between the Company and Danforth Advisors, LLC. He receives no direct compensation from the Company.
Management Commentary and Background
Mr. Murphy, age 67, has served as an interim CFO for public and private life science companies through Danforth since 2012. His prior experience includes serving as CFO at OxiGene, Inc. (2004–2012) and starting his career at Sepracor Inc. in 1990. The Company confirmed no family relationships exist between Mr. Murphy and current directors or officers, and no undisclosed material transactions exist.
Investor Verification Checklist
- Verify the terms of the Danforth Consulting Agreement (Exhibit 99.1) to understand the fee structure paid to the advisory firm.
- Confirm the duration of the "Interim" status for the CFO role and any plans for a permanent appointment.
- Review recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial statements.